OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
January 31, 2024 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of...
CT Scanner Market Size Worth USD 10.57 Billion in 2032 | Emergen Research
January 29, 2024 10:13 ET
|
Emergen Research
Vancouver, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The global Computed tomography (CT) scanner market size was USD 6.20 Billion in 2022 and is expected to register a rapid revenue CAGR of 5.4% during the...
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
December 04, 2023 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of...
Survey Finds Nearly 1 in 2 Americans are Concerned About Contracting an Infectious Disease from a Hospital
November 09, 2023 08:00 ET
|
Kinnos
New survey finds Americans are concerned about hospital cleanliness and getting sick or contracting an infectious disease from a hospital.
RetinalGeniX Technologies Inc. Focuses on Prevention of Blindness and Early Detection of Multiple Systemic Diseases
September 18, 2023 05:59 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) released to the public via OTC Markets, a video webinar regarding...
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
September 08, 2023 07:00 ET
|
OKYO Pharma LTD
Full enrollment achieved on September 6th with a total of 240 patients enrolled in studyTop-line data planned for release in December 2023Phase 2 trial is designed as a potential registration trial,...
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)
August 30, 2023 07:00 ET
|
OKYO Pharma LTD
Full enrollment anticipated by first week of SeptemberOKYO on schedule to release top-line data before end of 2023Phase 2 trial is designed as potential registration trial with pre-specified primary...
RetinalGenix Technologies Inc. Announces the Addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS
August 28, 2023 06:35 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Fred Chasalow, Ph.D., to the...
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
August 03, 2023 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter...
[Latest] Global Human Insulin Market Size/Share Worth USD 70.68 Billion by 2030 at a 8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
July 20, 2023 12:30 ET
|
Custom Market Insights
Austin, TX, USA, July 20, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Human Insulin Market Size, Trends and Insights By Type (Modern Human Insulin,...